Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$127.69 USD

127.69
1,118,217

-0.12 (-0.09%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $127.70 +0.01 (0.01%) 6:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

The Zacks Analyst Blog Highlights: United Natural Foods, The Boston Beer Company, DaVita, Owens & Minor and Primo Water Corp

by Zacks Equity Research

The Zacks Analyst Blog Highlights: United Natural Foods, The Boston Beer Company, DaVita, Owens & Minor and Primo Water Corp

Zacks Equity Research

The Zacks Analyst Blog Highlights: FedEx, Whirlpool, The Boston Beer Company, Laboratory Corporation of America and DaVita

by Zacks Equity Research

The Zacks Analyst Blog Highlights: FedEx, Whirlpool, The Boston Beer Company, Laboratory Corporation of America and DaVita

Anirudha Bhagat headshot

6 Stocks Near 52-Week Highs Poised to Appreciate Further

by Anirudha Bhagat

Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.

Zacks Equity Research

Acadia Healthcare (ACHC) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Acadia Healthcare (ACHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sreoshi Bera headshot

5 Safe Stocks to Sail Through the US Election Uncertainties

by Sreoshi Bera

Rise in coronavirus cases and uncertainties revolving around the election might keep markets volatile for some time. Here are five stocks to invest in and play safe.

Nalak Das headshot

Wall Street Suffers Back-to-Back Monthly Decline: What Next?

by Nalak Das

At this stage, it will be prudent to invest in large-cap growth/momentum stocks like Zoom Video (ZM), FedEx (FDX), Whirlpool (WHR), The Boston Beer (SAM), Laboratory Corp. (LH), RPM Intetnational (RPM), Brown & Brown (BRO) and DaVita (DVA).

Zacks Equity Research

New Strong Buy Stocks For November 2nd

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss

by Zacks Equity Research

DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.

Zacks Equity Research

DaVita HealthCare (DVA) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 20.81% and -0.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More

by Zacks Equity Research

Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.

Zacks Equity Research

Are Investors Undervaluing DaVita HealthCare (DVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.

Zacks Equity Research

New Strong Buy Stocks for October 26th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Zacks Equity Research

Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (DVA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Higher Testing Volume to Aid LabCorp's (LH) Q3 Earnings

by Zacks Equity Research

In Q3, LabCorp (LH) significantly expands accessibility of PCR testing to reach underserved communities.

Zacks Equity Research

Baxter Supports Findings of Ongoing COVID-19 Nutrition Study

by Zacks Equity Research

The study, supported by Baxter (BAX) through an investigator-initiated grant, is the first analysis of longitudinal REE in critically ill, mechanically-ventilated COVID-19 patients.

Zacks Equity Research

Here's Why You Should Invest in AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

Zacks Equity Research

LHC Group (LHCG) and CHRISTUS Health Extend JV Partnership

by Zacks Equity Research

LHC Group (LHCG) and CHRISTUS Health expand their partnership to boost home health services and hospice care.

Zacks Equity Research

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.

Zacks Equity Research

Here's Why You Should Retain AMN Healthcare (AMN) Stock Now

by Zacks Equity Research

AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.

Zacks Equity Research

Allscripts Completes Sale of EPSi Business to Strata

by Zacks Equity Research

Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.

Zacks Equity Research

Higher Testing to Aid Quest Diagnostics' (DGX) Q3 Earnings

by Zacks Equity Research

Quest Diagnostics (DGX) is expected to report strong improvement in COVID-19 antibody and molecular diagnostic testing volume in Q3.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health